NeoImmuneTech, Inc. Logo

NeoImmuneTech, Inc.

A clinical-stage biopharma developing T cell-focused immuno-therapeutics for diseases.

950220 | KO

Overview

Corporate Details

ISIN(s):
KR8840140006
LEI:
Country:
United States of America
Address:
2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville

Description

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-09-18 00:00
주식등의대량보유상황보고서(일반)
Korean 94.2 KB
2025-09-16 00:00
증권발행결과(자율공시) (주주배정 후 실권주 일반공모)
Korean 7.8 KB
2025-09-16 00:00
증권발행실적보고서
Korean 90.0 KB
2025-09-15 00:00
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 11.0 KB
2025-09-10 00:00
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 9.6 KB
2025-09-04 00:00
유상증자최종발행가액확정 (주주배정후 실권주 일반공모)
Korean 11.3 KB
2025-09-04 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 38.3 KB
2025-09-04 00:00
[발행조건확정]증권신고서(증권예탁증권)
Korean 218.3 KB
2025-09-04 00:00
[기재정정]투자설명서
Korean 2.7 MB
2025-08-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-20 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-08-20 00:00
주식등의대량보유상황보고서(일반)
Korean 99.8 KB

Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeoImmuneTech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.